Diagnostics IPO That Shocked the SME Market

The Indian primary market has witnessed a renewed surge of investor enthusiasm, particularly in the SME segment, and the Modern Diagnostic & Research Centre Limited IPO stands out as one of the most aggressively subscribed issues in recent times. With an overall subscription of 376.90 times, the IPO attracted massive interest across investor categories, reflecting strong confidence in the company’s business model, growth trajectory, and the broader diagnostics sector in India.

This article provides a comprehensive 360-degree review of the Modern Diagnostic & Research Centre IPO, including issue details, subscription analysis, listing performance, company background, financials, strengths, risks, and long-term outlook

Table of Contents

1. Introduction to the IPO

2. Modern Diagnostic & Research Centre IPO: Key Details

3. Subscription Breakdown & Investor Response

4. IPO Timeline & Important Dates

5. Listing Performance on BSE SME

6. About Modern Diagnostic & Research Centre Limited

7. Business Model & Service Portfolio

8. Operational Footprint & Expansion Strategy

9. Industry Overview: Diagnostics in India

10. Financial Performance Analysis

11. Balance Sheet Strength & Capital Structure

12. Profitability, Margins & Efficiency

13. Use of IPO Proceeds

14. Key Strengths of the Company

15. Risk Factors & Concerns

16. Valuation Perspective

17. Peer Comparison (SME Diagnostics Space)

18. Post-Listing Performance Outlook

19. Long-Term Growth Drivers

20. Conclusion: Should Investors Track MDRC?

1. Introduction to the IPO

The Modern Diagnostic & Research Centre IPO emerged as one of the most talked-about SME public issues of the year. The extraordinary demand—especially from non-institutional investors—signals not only optimism toward the company but also increasing appetite for healthcare and diagnostics-focused businesses.

With healthcare becoming a structural growth theme in India, diagnostic service providers offering integrated pathology and radiology solutions are gaining both operational relevance and investor attention.

2. Modern Diagnostic & Research Centre IPO: Key Details

The IPO was structured as a book-building issue, entirely comprising a fresh issue of shares.

IPO Highlights

• Issue Size: ₹36.89 crore (approximately ₹37 crore)

• Fresh Issue: 40,99,200 equity shares

• Face Value: ₹10 per share

• Price Band: ₹85 to ₹90 per share

• Lot Size: 1,600 shares

• Issue Type: Book-building IPO

• Listing Platform: BSE SME

The absence of an offer for sale (OFS) indicates that all proceeds are intended to strengthen the company’s balance sheet and support growth initiatives.

3. Subscription Breakdown & Investor Response

The subscription numbers highlight extraordinary investor enthusiasm.

Overall Subscription: 376.90 times

Category-wise Subscription

• Qualified Institutional Buyers (QIBs): 193.51 times

• Non-Institutional Investors (NIIs): 702.08 times

• Retail Investors: 33.26 times

The exceptionally high NII participation suggests strong interest from high-net-worth individuals and seasoned market participants, often considered a positive signal in SME IPOs.

4. IPO Timeline & Important Dates

The issue saw brisk subscription throughout the bidding window, with demand peaking on the final day.

5. Listing Performance on BSE SME

On its debut on the BSE SME platform, Modern Diagnostic & Research Centre shares were listed at:

• Listing Price: ₹99.50 per share

• Issue Price: ₹90 per share

• Listing Premium: ₹9.50 per share

• Listing Gain: 10.56%

The positive listing reinforced investor confidence, though the premium was relatively moderate compared to the massive oversubscription—suggesting realistic pricing and healthy market discipline.

6. About Modern Diagnostic & Research Centre Limited

Modern Diagnostic & Research Centre Limited (MDRC) is a well-established diagnostic service provider in India. While the company’s formal incorporation dates back to 2016, its operational legacy traces back to 1985, reflecting decades of experience in the diagnostics domain.

The company operates as an integrated diagnostics chain, delivering both pathology and radiology services to individual patients, hospitals, clinics, and institutional clients.

7. Business Model & Service Portfolio

MDRC’s business model is centered on end-to-end diagnostic solutions, combining accuracy, accessibility, and scalability.

Key Services Offered

• Pathology testing

• Radiology services

• Ultrasound, CT, MRI, and X-ray

• ECG and Pulmonary Function Tests (PFT)

• Specialized heart and neuro diagnostic labs

• Home sample collection services

• Digital report delivery and online access

The company also provides customized diagnostic packages for corporates, hospitals, and institutional clients, enhancing recurring revenue streams.

8. Operational Footprint & Expansion Strategy

As per the latest data, MDRC operates:

• 21 diagnostic facilities

  • 18 laboratories

  • 3 diagnostic centres

• Presence across 8 Indian states

This multi-state footprint helps diversify revenue sources while reducing geographic concentration risk. The IPO proceeds are expected to support further expansion, technology upgrades, and working capital needs.

9. Industry Overview: Diagnostics in India

India’s diagnostics industry is one of the fastest-growing segments within healthcare, driven by:

• Rising preventive healthcare awareness

• Increasing lifestyle diseases

• Growing elderly population

• Expansion of health insurance coverage

• Technological advancements in testing

Diagnostics typically offer asset-heavy but cash-generative models, with strong operating leverage once scale is achieved—making companies like MDRC attractive in the long term.

10. Financial Performance Analysis

An analysis of Modern Diagnostic & Research Centre Limited’s financials reveals significant improvement in scale, profitability, and net worth.

Key Financials (₹ in crore)

11. Balance Sheet Strength & Capital Structure

The steady increase in net worth and reserves indicates improving internal accruals, though borrowings remain notable—an area to monitor post-IPO.

12. Profitability, Margins & Efficiency

• Revenue Growth (FY24–FY25): ~15%

• PAT Growth (FY24–FY25): ~55%

• EBITDA Growth: Strong expansion driven by operating leverage

The turnaround from losses in FY23 to healthy profitability in FY25 reflects improved cost control, better utilization of diagnostic assets, and scale benefits.

13. Use of IPO Proceeds

The proceeds from the fresh issue are expected to be used for:

• Expansion of diagnostic centres and labs

• Purchase of advanced diagnostic equipment

• Working capital requirements

• General corporate purposes

These investments are aligned with revenue growth and margin expansion objectives.

14. Key Strengths of the Company

1. Integrated diagnostics model covering pathology and radiology

2. Established brand legacy with decades of operational experience

3. Wide service portfolio, including specialized tests

4. Geographic diversification across eight states

5. Improving financial performance and profitability

6. Strong IPO demand, validating market confidence

15. Risk Factors & Concerns

• High competition from national diagnostic chains

• Capital-intensive nature of radiology equipment

• Dependence on skilled medical professionals

• Borrowing levels that need prudent management

• SME liquidity risks post-listing

16. Valuation Perspective

At the upper price band of ₹90, the valuation appears reasonable compared to growth prospects, especially considering the company’s improving margins and expanding footprint. The moderate listing premium suggests the IPO was not excessively priced.

17. Peer Comparison (SME Diagnostics Space)

Compared to other SME diagnostic players, MDRC benefits from:

• Broader service coverage

• Better revenue visibility

• Stronger recent profitability

However, scale remains smaller than national chains, making execution critical.

18. Post-Listing Performance Outlook

Post-listing, the stock’s performance will likely depend on:

• Quarterly earnings consistency

• Expansion execution

• Debt management

• Broader SME market sentiment

Given the solid fundamentals, the company could attract long-term investors rather than purely speculative interest.

19. Long-Term Growth Drivers

• Rising healthcare spending in India

• Preventive diagnostics trend

• Corporate and institutional tie-ups

• Expansion into underserved regions

• Technology-enabled diagnostics

20. Conclusion: Should Investors Track MDRC?

The Modern Diagnostic & Research Centre IPO represents a strong SME healthcare listing, backed by impressive subscription numbers, improving financials, and a scalable business model. While risks remain, especially typical SME-related concerns, the company’s growth trajectory and sector tailwinds make it a stock worth tracking for investors with a medium-to-long-term horizon.

In summary, MDRC’s IPO debut reinforces the growing importance of diagnostics in India’s healthcare ecosystem—and positions the company as a credible emerging player in this space.

ALSO READ: ETF Portfolio for Aggressive Investors